PDPenny Grewal Daumerie

Penny Grewal Daumerie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Penny Grewal Daumerie has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study

    by Ambrose O Talisuna, Penny Grewal Daumerie, Andrew Balyeku, Timothy Egan, Bram Piot, Renia Coghlan, Maud Lugand, Godfrey Bwire, John Bosco Rwakimari, Richard Ndyomugyenyi, et al.

    Artemisinin-based combination therapy (ACT), the treatment of choice for uncomplicated falciparum malaria, is unaffordable and generally inaccessible in the private sector, the first port of call for most malaria treatment across rural Africa. Between August 2007 and May 2010, the Uganda Ministry of Health and the Medicines for Malaria Venture conducted the Consortium for ACT Private Sector Subsidy (CAPSS) pilot study to test whether access to ACT in the private sector could be improved through the provision of a high level supply chain subsidy.


  • Open Access

    Patient-centred tuberculosis treatment delivery under programmatic conditions in Tanzania: a cohort study

    by Saidi Egwaga, Abdallah Mkopi, Nyagosya Range, Vera Haag-Arbenz, Amuri Baraka, Penny Grewal, Frank Cobelens, Hassan Mshinda, Fred Lwilla, Frank van Leth

    Directly observed therapy (DOT) remains the cornerstone of the global tuberculosis (TB) control strategy. Tanzania, one of the 22 high-burden countries regarding TB, changed the first-line treatment regimen to contain rifampicin-containing fixed-dose combination for the full 6 months of treatment. As daily health facility-based DOT for this long period is not feasible for the patient, nor for the health system, Tanzania introduced patient centred treatment (PCT). PCT allows patients to choose for daily DOT at a health facility or at their home by a supporter of choice. The introduction of fixed dose combinations in the intensive and continuation phase made PCT feasible by eliminating the risk of selective drug taking by patients and reducing the number of tablets to be taken. The approach was tested in three districts with the objective to assess the effect of this strategy on TB treatment outcomes